Display options
Cite
King J, Adra N, Einhorn LH. Testicular Cancer: Biology to Bedside. Cancer Res. 2021;81(21):5369-5376doi: 10.1158/0008-5472.CAN-21-1452.
King, J., Adra, N., & Einhorn, L. H. (2021). Testicular Cancer: Biology to Bedside. Cancer research, 81(21), 5369-5376. https://doi.org/10.1158/0008-5472.CAN-21-1452
King, Jennifer, et al. "Testicular Cancer: Biology to Bedside." Cancer research vol. 81,21 (2021): 5369-5376. doi: https://doi.org/10.1158/0008-5472.CAN-21-1452
King J, Adra N, Einhorn LH. Testicular Cancer: Biology to Bedside. Cancer Res. 2021 Nov 01;81(21):5369-5376. doi: 10.1158/0008-5472.CAN-21-1452. Epub 2021 Aug 11. PMID: 34380632.
Copy Download .nbib Format: NLM
Share it on

Cancer Res. 2021 Nov 01;81(21):5369-5376. doi: 10.1158/0008-5472.CAN-21-1452. Epub 2021 Aug 11.

Testicular Cancer: Biology to Bedside.

Cancer research

Jennifer King, Nabil Adra, Lawrence H Einhorn

Affiliations

  1. Division of Hematology and Medical Oncology - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana.
  2. Division of Hematology and Medical Oncology - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana. [email protected].

PMID: 34380632 DOI: 10.1158/0008-5472.CAN-21-1452

Abstract

Testicular cancer is the first solid tumor with a remarkably high cure rate. This success was only made possible through collaborative efforts of basic and clinical research. Most patients with distant metastases can be cured. However, the majority of these patients are diagnosed at a young age, leaving many decades for the development of treatment-related complications. This has magnified the importance of research into survivorship issues after exposure to platinum-based chemotherapy. This research, along with research into newer biomarkers that will aid in the diagnosis and surveillance of patients and survivors of testicular cancer, will continue to advance the field and provide new opportunities for these patients. There also remains the need for further therapeutic options for patients who unfortunately do not respond to standard treatment regimens and ultimately die from this disease, including a cohort of patients with late relapses and platinum-refractory disease. Here we discuss the advancements in management that led to a highly curable malignancy, while highlighting difficult situations still left to solve as well as emerging research into novel biomarkers.

©2021 American Association for Cancer Research.

References

  1. Cancer of the testis: trends in SEER incidence and US mortality. - PubMed
  2. Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update. 2006;12:303–23. - PubMed
  3. Lobo J, Costa AL, Vilela-Salgueiro B, Rodrigues A, Guimaraes R, Cantante M, et al. Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists. Hum Path. 2018;82:113–24. - PubMed
  4. Cheng L, Lyu B, Roth LM. Perspectives on testicular germ cell neoplasms. Hum Pathol. 2017;59:10–25. - PubMed
  5. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson AM, Eisenberg ML, et al. Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. Physiol Rev. 2016;96:55–97. - PubMed
  6. Skotheim RI, Lothe RA. The testicular germ cell tumour genome. APMIS. 2003;111:136–50. - PubMed
  7. Atkin NB, Baker MC. Specific chromosome change, i(12p), in testicular tumours?. Lancet. 1982;2:1349. - PubMed
  8. Carcasole AA, van Schaik RH, Zeinstra LM, Wierikx CD, van Gurp RJ, van den Pol M, et al. Human growth-differentiation factor 3(hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours. Oncogene. 1998;16:95–103. - PubMed
  9. Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, Jones SB, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A. 2003;23:13350–5. - PubMed
  10. Houldsworth J, Reuter V, Bosl GJ, Chaganti RS. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ. 1997;8:293–9. - PubMed
  11. Ottesen AM, Skakkebaek NE, Lundsteen C, Leffers H, Larsen J, Rajpert-De Meyts E. High-resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor development. Genes Chromosomes Cancer. 2003;38:117–25. - PubMed
  12. Roelofs H, Mostert MC, Pompe K, Zafarana G, van Oorchot M, van Gurp RJ, et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol. 2000;157:1155–66. - PubMed
  13. Looigenga LHJ, Zafarana G, Grygalewicz B, Summersgill B, Debiec-Rychter M, Veltman J, et al. Role of gain of 12p in germ cell tumour development. APMIS. 2003;111:161–71. - PubMed
  14. Wang Z, McGlynn KA, Rajpert-De Meyts E, Bishop DT, Chung CC, Dalgaard MD, et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nat Genet. 2017;49:1141–7. - PubMed
  15. Li MC, Whitmore WF, Golbey R, Grabstald H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA. 1960;174:1291–9. - PubMed
  16. MacKenzie AR. Chemotherapy of metastatic testis cancer- results in 154 patients. Cancer. 1966;19:1369–76. - PubMed
  17. Barranco SC, Humphrey RM. The effects of bleomycin on survival and cell progression in Chinese hamster cells in vitro. Cancer Res. 1971;31:1218–23. - PubMed
  18. Samuels ML, Lansotti VJ, Boyle LE, Holoye PY, Johnson DE. An update of the velban-bleomycin program in testicular neoplasia with a note on cis-dichlorodiammineplatinum. Cancer of the Genitourinary Tract. 1979;159–72. - PubMed
  19. Rosenberg B, VanCamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–9. - PubMed
  20. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–6. - PubMed
  21. Rosenberg B, VanCamp L. The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 1970;20:1799–802. - PubMed
  22. Prestyako AW, D'Aoust JC, Issell BF. CST cisplatin. Cancer Treat Rev. 1979;6:17–39. - PubMed
  23. Cavalli F, Sonntag RW, Ryssel HJ, Tschopp L, Brunner KW. First therapeutic experience with cis-platinum(II)diagmindichloride (NSC 119875) in metastasizing ovarian and testicular carcinoma. Schweiz Med Wochenschr. 1976;106:754–7. - PubMed
  24. Chary KK, Higby DJ, Henderson ES, Swinerton KD. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treat Rep. 1977;61:367–70. - PubMed
  25. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87:293–8. - PubMed
  26. Fitzharris B, Kaye S, Saverymuttu S, Newlands E, Barrett A, Peckham M, et al. VP 16–213 as a single agent in advanced testicular tumors. Eur J Cancer. 1980;16:1193. - PubMed
  27. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–40. - PubMed
  28. Hinton S, Catalano PJ, Nichols CR, Crawford ED, Vogelzang N, Trump D, et al. Cisplatin, etoposide, and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Cancer. 2003;97:1869–75. - PubMed
  29. Funt SA, McHugh DJ, Tsai S, Knezevic A, O'Donnell D, Patil S, et al. Four cycles of etoposide plus cisplatin for patients with good-risk advanced germ cell tumors. Oncologist. 2021;26:483–91. - PubMed
  30. Mead GM, Stenning SP. The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumors. J Clin Oncol. 1997;15:594–603. - PubMed
  31. Beyer J, Collette L, Sauve N, Daugaard G, Feldman DR, Tandstad T. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J Clin Oncol. 2021;39:1553–62. - PubMed
  32. Gillessen S, Suave N, Collette L, Daugaard G, de Wit R, Albany C. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021;39:1563–74. - PubMed
  33. Albany C, Adra N, Snavely AC, Cary C, Masterson TA, Foster RS, et al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol. 2018;29:341–6. - PubMed
  34. Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32:3085–92. - PubMed
  35. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, et al. Dose-intensive chemotherapy in refractory germ cell cancer- a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7:932–9. - PubMed
  36. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–8. - PubMed
  37. Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: The Indiana University experience. J Clin Oncol. 2017;35:1096–102. - PubMed
  38. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J. Combination of paclitaxel, ifosfamide and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23:6549–55. - PubMed
  39. Loehrer PJ, Gonin R, Nichols C, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–4. - PubMed
  40. Standard-dose combination chemotherapy or high-dose combination chemotherapy and stem cell transplant in treating patients with relapsed or refractory germ cell tumors. 2015. - PubMed
  41. Kollmansberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Rick O, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the german testicular cancer study group. J Clin Oncol. 2004;22:108–14. - PubMed
  42. Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel T, Vaughn D. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the eastern cooperative oncology group. J Clin Oncol. 2002;20:1859–63. - PubMed
  43. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007;25:513–6. - PubMed
  44. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355:1075–6. - PubMed
  45. Hellesnes R, Myklebust TA, Fossa SD, Bremnes RM, Karlsdottir A, Kyammen O, et al. Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol. 2021;29. - PubMed
  46. Kier MG, Hansen MK, Lauritsen J, Mortensen MS, Bandak M, Agerbaek M, et al. Second malignant neoplasms and cause of death in patients with germ cell cancer. A Danish nationwide cohort study. JAMA Oncol. 2016;2:1624–7. - PubMed
  47. Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989;7:754–60. - PubMed
  48. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34:2712–20. - PubMed
  49. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, Charif OE, Mapes B, et al. Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res. 2017;23:3325–33. - PubMed
  50. Cryns K, Sivakumaran TA, Van den Ouweland JMW, Pennings RJE, Cremers CWRJ, Flothmann K, et al. Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat. 2003;22:275–87. - PubMed
  51. Fonseca SG, Ishigaki S, Oslowski CM, Lu S, Lipson KL, Ghosh R, et al. Wolfran syndrome I gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest. 2010;120:744–55. - PubMed
  52. Mandic A, Hannson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 2003;278:9100–6. - PubMed
  53. Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RF, Vaughn DJ. Clinical and genome-wide analysis of multiple severe cisplatin-induced neurotoxicities in adult-onset cancer survivors. Clin Cancer Res. 2020;26:6550–8. - PubMed
  54. Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, et al. Fertility, gonadal, and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93:200–7. - PubMed
  55. Khanal N, Ahmed SS, Kalra M, Miller TJ, Brames MJ, Stump TE, et al. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy. Support Care Cancer. 2020;28:3165–70. - PubMed
  56. Ondrusova M, Spanikova B, Sevcikova K, Ondrus D. Testosterone deficiency and bone metabolism damage in testicular cancer survivors. Am J Mens Health. 2018;12:628–33. - PubMed
  57. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28:4649–57. - PubMed
  58. Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw. 2012;10:537–44. - PubMed
  59. Abu Zaid M, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, et al. Clinical and genetic risk factors for adverse metabolic outcomes in North American testicular cancer survivors. Natl Compr Canc Netw. 2018;16:257–65. - PubMed
  60. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5. - PubMed
  61. de Haas EC, Altena R, Boezen HM, Zwart N, Smit AJ, Bakker SJL, et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol. 2013;24:749–55. - PubMed
  62. Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol. 2007;18:241–8. - PubMed
  63. Westerink NL, Nuver J, Lefrandt JD, Vrieling AH, Gietema JA, Walenkamp AME. Cancer treatment induced metabolic syndrome: improving outcomes with lifestyle. Crit Rev Oncol Hematol. 2016;108:128–36. - PubMed
  64. Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol. 2006;29:12–3. - PubMed
  65. Rick O, Braun T, Siegert W, Beyer J. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer. 2006;42:1775–9. - PubMed
  66. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010;28:523–8. - PubMed
  67. Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Calareso G, Togliardi E, et al. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Ann Oncol. 2017;28:1346–51. - PubMed
  68. Albany C, Einhorn L, Garbo L, Garbo L, Boyd T, Josephson N, et al. Treatment of CD30-expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: identification and report of seven cases. Oncologist. 2018;23:316–23. - PubMed
  69. Adra N, Einhorn LH, Althouse SK, Ammakkanavar NR, Musapatika D, Albany D, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2018;29:209–14. - PubMed
  70. Adra N, Vaughn DJ, Einhorn L, Hanna NH, Rosales M, Arozullah A, et al. A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors. J Clin Oncol. 2020;38. - PubMed
  71. Ashkar R, Feldman DR, Adra N, Abu Zaid M, Funt SA, Althouse SK, et al. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. Invest New Drugs. 2021. - PubMed
  72. Bagrodia A, Lee BH, Lee W, Cha EK, Sfakanos JP, Iyer G, et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016;33:4000–7. - PubMed
  73. Taylor-Weiner A, Zack T, O'Donnell E, Guerriero JL, Bernard B, Reddy A, et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016;540:114–8. - PubMed
  74. Goudarzi KM, Lindstrom MS. Role of ribosomal protein mutations in tumor development (Review). Int J Oncol. 2016;48:1313–24. - PubMed
  75. Akel R, Anouti B, Kern S, Cary C, Masterson TA, Jacob JM, et al. Comprehensive genomic profiling (CGP) in patients with relapsed/refractory germ-cell tumors (GCT). J Clin Oncol. 2020;38. - PubMed
  76. Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and hilda rosenthal foundation award lecture. Cancer Res. 1981;41:3275–80. - PubMed
  77. George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003;21:113–22. - PubMed
  78. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol. 1995;13:1170–6. - PubMed
  79. Ganjoo KN, Foster RS, Michael H, Donohue JP, Einhorn LH. Germ cell tumor associated primitive neuroectodermal tumors. J Urol. 2001;165:1514–6. - PubMed
  80. Ehrlich Y, Beck SDW, Ulbright TM, Cheng L, Brames MJ, Andreoiu M, et al. Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol. 2010;21:1846–50. - PubMed
  81. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol. 2000;18:204–13. - PubMed
  82. Ulbright TM, Hattab EM, Zhang S, Ehrlich Y, Foster RS, Einhorn LH, et al. Primitive neuroectodermal tumors in patients with testicular germ cell tumors usually resemble pediatric-type central nervous system embryonal neoplasms and lack chromosome 22 rearrangements. Mod Pathol. 2010;23:972–80. - PubMed
  83. Loehrer PJ, Hui S, Clark S, Seal M, Einhorn LH, Williams SD, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminatous germ cell tumors: a clincopathological correlation. J Urol. 1986;135:1183–9. - PubMed
  84. Ulbright TM, Loehrer PJ, Roth LM, Einhorn LH, Williams SD, Clark SA. The development of non-germ cell malignancies within germ cell tumors. A clincopathologic study of 11 cases. Cancer. 1984;54:1824–33. - PubMed
  85. Al-Hader AA, Jain A, Al-Nasrallah N, Einhorn LH. Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy. Am J Clin Oncol. 2015;38:364–6. - PubMed
  86. Javadpour N. The role of biologic tumor markers in testicular cancer. Cancer. 1980;45:1755–61. - PubMed
  87. Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat Rev Urol. 2016;13:715–25. - PubMed
  88. Dieckmann KP, Richter-Simonsen H, Kulejewski M, Ikogho R, Zecha H, Anheuser P, et al. Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation. Urol Int. 2018;100:409–19. - PubMed
  89. Ehrlich Y, Beck SDW, Foster RS, Bihrle R, Einhorn LH. Serum tumor markers in testicular cancer. Urol Oncol. 2013;31:17–23. - PubMed
  90. Waldmann TA, McIntire KR, Suer ME, Blackman MA, Princler GL. The use of a radioimmunoassay for alpha-fetoprotein in the diagnosis of malignancy. Cancer. 1974;34:1510–5. - PubMed
  91. Masopust J, Kithier K, Radl J, Koutecky J, Kotal L. Occurrence of fetoprotein in patients with neoplasms and non-neoplastic disease. Int J Cancer. 1968;3:364–73. - PubMed
  92. Odell WD, Griffin J. Pulsatile secretion of human gonadotropin in normal adults. N Engl J Med. 1987;317:1688–91. - PubMed
  93. Garnick MB. Spurious rise in human chorionic gonadotropin induced by marijuana in patients with testicular cancer. N Engl J Med. 1980;303:1177. - PubMed
  94. Ahmad A. Non-coding RNAs: a tale of junk turning into treasure. Noncoding RNA Res. 2016;1:1–2. - PubMed
  95. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69. - PubMed
  96. Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, et al. Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol. 2019;37:1412–23. - PubMed
  97. Palmer RD, Murray MJ, Saini HK, van Dongen S, Abreu-Goodger C, Muralidhar B, et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 2010;70:2911–23. - PubMed
  98. Gillis AJM, Rijlaarsdam MA, Eini R, Dorssers LCJ, Biermann K, Murray MJ, et al. Targeted serum mi-RNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol Oncol. 2013;7:1083–92. - PubMed
  99. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, et al. Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum. J Clin Oncol. 2019;37:3090–8. - PubMed

Publication Types